Background: Pioglitazone is a safe and effective option to manage patients with
| INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a prevalence that is increasing in parallel with the obesity epidemic in both the USA and worldwide. [1] [2] [3] In a study that used the sensitive and quantitative technique proton-magnetic resonance spectroscopy to measure hepatic triglyceride content, the prevalence of hepatic steatosis was 31%. 4 The established risk factors for NAFLD are obesity, type 2 diabetes, and metabolic syndrome. 5 Nonalcoholic fatty liver disease varies from relatively benign isolated steatosis, characterised by the accumulation of fat in the liver, to nonalcoholic steatohepatitis (NASH), where hepatic steatosis and inflammation with ballooning injury is present with or without fibrosis. 5, 6 Nonalcoholic steatohepatitis can further progress to liver cirrhosis and hepatocellular carcinoma 5 and is a rapidly growing indication for liver transplantation. 7 The Handling Editor for this article was Professor Stephen Harrison, and it was accepted for publication after full peer-review.
Currently, the standard of care is lifestyle modification. 5 The use of pioglitazone for NASH may be recommended based on several clinical studies showing improvement in liver histology scores and surrogate biomarkers. 5, [8] [9] [10] [11] [12] However, limitations include that the response to pioglitazone are variable and improvement is not achieved in all treated patients. For example, in the PIVENS trial, 34% and 47% of the patients in the pioglitazone arm achieved the primary outcome and resolution of NASH respectively. 13 The reason why NASH improves in some but not all patients treated with pioglitazone is not understood. Thus, it is important to understand possible factors that may identify patients who are or are not likely to improve with pioglitazone treatment to optimise pharmacotherapy.
These factors can help clinicians evaluate the benefit and risk of the treatment and assist in making therapeutic decisions. Currently, it is not known whether pioglitazone concentrations and other baseline characteristics are predictive of clinical outcome.
The relationship between pioglitazone plasma concentration and improvement in NAFLD has not been established. We hypothesised that the drug concentration achieved differs among patients with NAFLD and that the difference in the drug concentrations contributes to variability in clinical outcomes. Pioglitazone is metabolised in the liver mainly by CYP2C8 and to a lesser extent by CYP3A4 to two major active metabolites, hydroxypioglitazone (also known as M-IV) and ketopioglitazone (M-III). 14, 15 The role of the active metabolites in the treatment of NAFLD is also unknown. The objectives of this study were to establish the pioglitazone concentra- The primary outcome was defined as a ≥ 2-point reduction in NAFLD activity score (NAS) 16 with at least a one-point improvement in more than one liver histology category and without worsening of fibrosis. Resolution of NASH, individual liver biopsy score (steatosis, inflammation, allooning, and fibrosis), and NAS were also examined as secondary outcomes.
| Analytic procedures and measurements
Plasma glucose was measured in the Clinical Research Center by the glucose oxidase method (Analox Glucose Analyzer, Analox Instruments, Lunenburg, MA, USA). For other analyses, blood samples were placed on ice at the bedside, processed within 15-20 minutes, and frozen at À80°C until the samples were analysed. Blood samples for the analysis of drug concentration were collected prior to the morning dose, and it was assured that patients were on chronic pioglitazone and that the drug concentration was at steady-state. A novel liquid chromatography tandem mass spectrometry assay described previously was used to measure plasma concentrations of pioglitazone, hydroxypioglitazone and ketopioglitazone. 17 The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from a single measurement of fasting insulin and glucose.
Plasma insulin was determined by radioimmunoassay (Siemens, Los
Angeles, CA, USA). Adiponectin concentrations were measured by magnetic bead Milliplex technology (Luminex xMAP, Millipore, St.
Charles, MO, USA), and CK-18 levels were quantified by ELISA (M30-Apoptosense, DiaPharma, Columbus, OH, USA).
| Statistical analyses
The Mann-Whitney test was used to compare drug concentrations between patients who achieved and did not achieve the primary outcome and NASH resolution. The paired t-test was used to com- respectively (P=.049). Among participants who achieved and did not achieve the resolution of NASH, the pioglitazone exposure indices were 2.85AE1.38 and 1.78AE1.48 respectively (P=.018).
The liver biopsy results at baseline and after 18 months of pioglitazone treatment in these 54 patients are consistent with those in the full trial (Table S1 ). 10 The relationship between changes in NAS and pioglitazone exposure indices and between changes in adiponectin concentrations and pioglitazone exposure indices are described in Figure 2A and concentration. Change in fibrosis was not associated with drug concentrations.
In the multiple regression analysis, the parameters that were significant and included in the final model are summarised in Table 2. For the primary outcome, the only significant factors predicting the response were baseline NAS and pioglitazone exposure index. Pioglitazone exposure index was a better determinant of response than pioglitazone concentration alone. The performance of the model to predict the primary outcome is described in Table 3 . The area under the ROC curve was 0.77 for the primary outcome model (Figure 3 ). about 40%-50%, yielding a range in exposure (AUC) that is up to 10-fold. 21, 22 Genetic polymorphisms in CYP2C8 contribute to variability in pioglitazone metabolism. For example, the CYP2C8*3 haplotype is associated with increased metabolism of pioglitazone, yielding faster clearance and lower systemic pioglitazone concentrations. 23 This variant haplotype is found in Whites and Hispanics, but is not found in African-Americans. In addition, NASH and other inflammatory conditions affect the expression of CYP2C8, 24 while factors that do not appear to contribute to variability in CYP2C8-mediated metabolism include age and gender, which were shown to have no effect on CYP2C8 mRNA or protein expression in human liver. 25 A limitation of this study is that the exact drug administration time was not available, which may contribute to the observed variability in drug concentrations. However, even though the exact time since the last dose administered in each patient was unknown, the blood sample was taken prior to the morning dose, and fluctuations in drug concentrations around the trough were considered to be smaller. In addition, adherence to drug treatment was confirmed to be high. The elimination half-life of pioglitazone is relatively short, ranging from 3 to 7 hours, but for the metabolites are longer, ranging from 16 to 24 hours. 26 Thus, measuring the metabolite concentrations as a part of the pioglitazone exposure index provided a more stable measure of drug exposure. Another constraint is the limited number of factors considered to explain the outcomes. Although various baseline patient characteristics, as well as drug concentrations and biomarker levels, were considered, the best model from this study explained 18.6% of the total variability in the primary outcome. The possibility of other environmental and patient factors affecting the outcome cannot be ruled out, and further studies are warranted in a larger cohort.
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In conclusion, the results of this study demonstrate that pioglita- 
